The efficacy and prevalence of montelukast therapy in cough-variant asthma patients in al-kindy teaching hospital

Abstract

BACKGROUND: Cough-variant asthma (CVA) is a type of asthma in which the main symptom is a dry, non-productive cough. OBJECTIVE: The objective of the study was to evaluate the therapeutic effect of Montelukast in CVA and to investigate the prevalence of Montelukast in CVA. METHODS: A cross-sectional study was conducted on 30 patients with chronic cough at least 8 weeks using Montelukast at Al-Kindy Hospital over the period of January 2018‒March 2018. An interview using questionnaire was used to collect the data that were specifically prepared to meet the objective of study including age, sex, associated disease, exacerbation factors, and classical therapy. RESULTS: There was a reduction of the symptoms associated with CVA after treatment with Montelukast. The prevalence of exacerbation factors was as follows: Dust (73.3%) of patients, food (36.7%), exercise (60%), psychological (56.7%), smoking (30%), and others (perfume and cold weather) (26.7%). The usage of Montelukast in this study was 73.3% (22 patients). Patients using Montelukast have shown improvement of symptoms as follows: Chest pain was relieved from 57.1% of patients, exhaustion (58.3%), vomiting (76.5%), sleep disturbance (54.5%), affecting daily life in 57.1%, and syncope 66.7%. CONCLUSION: The prevalence of Montelukast administration to the patients with chronic cough in our study was found to be more than 70% of the 30 total patients. Montelukast usage leads to reduction in the frequency of chronic cough and the symptoms associated with it.